Search - tctmd.com

Displaying 1 - 20 of 68

Sort: Relevancy | Date

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Presentation TCT 2024

TCT 1012: Pre-Emptive PCI in Vulnerable Coronary Plaques Reduces Biomechanical and Anatomic High-Risk Features: The PROSPECT ABSORB Trial

Presenter: Diaa Hakim

October 29, 2024

Podcast TCTMD Talking Points

The PROSPECT ABSORB Trial

December 08, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

Shelley Wood

October 30, 2020

Presentation TCT 2020

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

Presenter: Gregg Stone

October 14, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

Presentation ESC 2018

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Presenter: Robert Byrne

August 29, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

Advertisement

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

TCT 1012: Pre-Emptive PCI in Vulnerable Coronary Plaques Reduces Biomechanical and Anatomic High-Risk Features: The PROSPECT ABSORB Trial

The PROSPECT ABSORB Trial

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

TCTMD’s Top 10 Most Popular Stories for October 2020

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Top News in Coronary Artery Disease: 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content